Robert J Morgan1, Timothy W Synold2, Jeffrey A Longmate3, David I Quinn4, David Gandara5, Heinz-Josef Lenz4, Christopher Ruel3, Bixin Xi2, Michael D Lewis6,7, A Dimitrios Colevas8,9, James Doroshow10,11, Edward M Newman2. 1. Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Duarte, CA, 91010, USA. rmorgan@coh.org. 2. Department of Cancer Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA. 3. Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA. 4. Division of Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, 90033, USA. 5. Division of Medical Oncology, University of California, Davis Cancer Center, Sacramento, CA, USA. 6. Eisai Research Institute, Andover, MA, 01810, USA. 7. Edward P. Evans Foundation, Casanova, VA, 20139, USA. 8. Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA. 9. Stanford Cancer Center, Stanford, CA, 94305, USA. 10. Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Duarte, CA, 91010, USA. 11. Division of Cancer Treatment and Diagnosis6, National Cancer Institute, Bethesda, MD, 20892, USA.
Abstract
BACKGROUND: The California Cancer Consortium completed a phase I trial of E7389 (eribulin mesylate), an analog of the marine natural product halichondrin B. This trial was to determine the pharmacodynamics, pharmacokinetics, and MTD of E7389 administered by bolus injection weekly for 3 weeks out of four. METHODS: This trial included a rapid titration design. Real-time pharmacokinetics were utilized to guide dose escalation. Initially, single-patient cohorts were enrolled with intra- and inter-patient dose doubling. The second phase was a standard 3 + 3 dose escalation schedule. At the MTD, a cohort of patients was enrolled for target validation studies (separate manuscript). The starting dose was 0.125 mg/m(2), and doses were doubled within and between patients in the first phase. Blood and urine sampling for E7389 pharmacokinetics was performed on doses 1 and 3 of cycle 1. Levels were determined using a LC/MS/MS assay. RESULTS: Forty patients were entered. Thirty-eight were evaluable for toxicity and 35 for response. The rapid escalation ended with a grade 3 elevation of alkaline phosphatase at 0.5 mg/m(2)/week. The second phase ended at 2.0 mg/m(2)/week with dose-limiting toxicities of grades 3 and 4 febrile neutropenia. Other toxicities included hypoglycemia, hypophosphatemia, and fatigue. The MTD was 1.4 mg/m(2)/week. Responses included four partial responses (lung cancer [2], urothelial [1], and melanoma [1]). CONCLUSIONS: E7389 was well tolerated in this trial with the major toxicity being myelosuppression. PD shows that E7389 induces significant morphologic changes (bundle formation) in the microtubules of peripheral blood mononuclear cells and tumor cells in vivo. The data suggest that lower intra-tumoral levels of β-tubulin III or higher intra-tumoral levels of MAP4 may correlate with response to E7389, while lower intra-tumoral levels of stathmin may be associated with progression. PK data reveal that E7389 exhibits a tri-exponential elimination from the plasma of patients receiving a rapid i.v. infusion. At sub-toxic doses, plasma concentrations of E7389 are maintained well above the levels required for activity in vitro for >72 h.
BACKGROUND: The California Cancer Consortium completed a phase I trial of E7389 (eribulin mesylate), an analog of the marine natural product halichondrin B. This trial was to determine the pharmacodynamics, pharmacokinetics, and MTD of E7389 administered by bolus injection weekly for 3 weeks out of four. METHODS: This trial included a rapid titration design. Real-time pharmacokinetics were utilized to guide dose escalation. Initially, single-patient cohorts were enrolled with intra- and inter-patient dose doubling. The second phase was a standard 3 + 3 dose escalation schedule. At the MTD, a cohort of patients was enrolled for target validation studies (separate manuscript). The starting dose was 0.125 mg/m(2), and doses were doubled within and between patients in the first phase. Blood and urine sampling for E7389 pharmacokinetics was performed on doses 1 and 3 of cycle 1. Levels were determined using a LC/MS/MS assay. RESULTS: Forty patients were entered. Thirty-eight were evaluable for toxicity and 35 for response. The rapid escalation ended with a grade 3 elevation of alkaline phosphatase at 0.5 mg/m(2)/week. The second phase ended at 2.0 mg/m(2)/week with dose-limiting toxicities of grades 3 and 4 febrile neutropenia. Other toxicities included hypoglycemia, hypophosphatemia, and fatigue. The MTD was 1.4 mg/m(2)/week. Responses included four partial responses (lung cancer [2], urothelial [1], and melanoma [1]). CONCLUSIONS:E7389 was well tolerated in this trial with the major toxicity being myelosuppression. PD shows that E7389 induces significant morphologic changes (bundle formation) in the microtubules of peripheral blood mononuclear cells and tumor cells in vivo. The data suggest that lower intra-tumoral levels of β-tubulin III or higher intra-tumoral levels of MAP4 may correlate with response to E7389, while lower intra-tumoral levels of stathmin may be associated with progression. PK data reveal that E7389 exhibits a tri-exponential elimination from the plasma of patients receiving a rapid i.v. infusion. At sub-toxic doses, plasma concentrations of E7389 are maintained well above the levels required for activity in vitro for >72 h.
Entities:
Keywords:
Eribulin; Halichondrin B analog; Pharmacodynamics; Pharmacokinetics; Phase I trial
Authors: Laura A Martello; Pascal Verdier-Pinard; Heng-Jia Shen; Lifeng He; Keila Torres; George A Orr; Susan Band Horwitz Journal: Cancer Res Date: 2003-03-15 Impact factor: 12.701
Authors: M J Towle; K A Salvato; J Budrow; B F Wels; G Kuznetsov; K K Aalfs; S Welsh; W Zheng; B M Seletsky; M H Palme; G J Habgood; L A Singer; L V Dipietro; Y Wang; J J Chen; D A Quincy; A Davis; K Yoshimatsu; Y Kishi; M J Yu; B A Littlefield Journal: Cancer Res Date: 2001-02-01 Impact factor: 12.701
Authors: Mary Ann Jordan; Kathryn Kamath; Tapas Manna; Tatiana Okouneva; Herbert P Miller; Celia Davis; Bruce A Littlefield; Leslie Wilson Journal: Mol Cancer Ther Date: 2005-07 Impact factor: 6.261
Authors: Hayley M McDaid; Sridhar Mani; Heng-Jia Shen; Franco Muggia; Daryl Sonnichsen; Susan Band Horwitz Journal: Clin Cancer Res Date: 2002-07 Impact factor: 12.531
Authors: Andrew J Robles; Raushan T Kurmasheva; Abhik Bandyopadhyay; Doris A Phelps; Stephen W Erickson; Zhao Lai; Dias Kurmashev; Yidong Chen; Malcom A Smith; Peter J Houghton Journal: Clin Cancer Res Date: 2020-03-17 Impact factor: 12.531
Authors: Eric S Schafer; Rachel E Rau; Stacey Berg; Xiaowei Liu; Charles G Minard; David D'Adamo; Rachael Scott; Larisa Reyderman; Gresel Martinez; Sandhya Devarajan; Joel M Reid; Elizabeth Fox; Brenda J Weigel; Susan M Blaney Journal: Pediatr Blood Cancer Date: 2018-05-02 Impact factor: 3.167
Authors: Robert A Parise; Joseph M Covey; Melinda G Hollingshead; Apurva K Srivastava; Timothy W Synold; Jan H Beumer Journal: J Pharm Biomed Anal Date: 2021-06-02 Impact factor: 3.571
Authors: Panagiotis Koliou; Vasilios Karavasilis; Maria Theochari; Seth M Pollack; Robin L Jones; Khin Thway Journal: Cancer Manag Res Date: 2018-02-01 Impact factor: 3.989
Authors: Michiko Sugawara; Krista Condon; Earvin Liang; Christopher DesJardins; Edgar Schuck; Kazutomi Kusano; W George Lai Journal: Cancer Chemother Pharmacol Date: 2017-06-29 Impact factor: 3.333
Authors: Thomas W Flaig; Ashish M Kamat; Donna Hansel; Molly A Ingersoll; H Barton Grossman; Cathy Mendelsohn; David DeGraff; Joseph C Liao; John A Taylor Journal: Bladder Cancer Date: 2017-07-27